Diabetes Clinical Trials in San Francisco

Showing 201-220 of 255 trials

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

NCT01681693

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. The investigators will study individuals with particular genotypes of the human organic cation transporter, (hOCT3), and the multidrug and toxin extrusion transporter, MATE1 to test the hypothesis that genetic variation in hOCT3 and hMATE1 are associated with variation in the pharmacokinetics and/or pharmacodynamics of the antidiabetic agent, metformin.

HealthyType 2 Diabetes Mellitus

University of California, San Francisco33 participantsStarted Feb 2010

San Francisco, California, United States

COMPLETEDNA< 1 mile

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

NCT01220336

Randomized control trial studying the effect of medical assistant health coaching for patients with diabetes, hypertension and hyperlipidemia within two San Francisco primary care community clinics, Mission Neighborhood Health Center and Southeast Health Center

DiabetesHypertensionHyperlipidemia

University of California, San Francisco441 participantsStarted Apr 2011

San Francisco, California, United States • San Francisco, California, United States

COMPLETEDPHASE313 miles

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867

This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin). The effect of dapagliflozin on weight and blood pressure will also be studied.

Type 2 Diabetes

AstraZeneca833 participantsStarted Oct 2009

Huntsville, Alabama, United States • Ozark, Alabama, United States • Anaheim, California, United States +85 more locations

Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans

Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions

Dapagliflozin DPPIV Inhibitor add-on Study

Diabetes Trials in Other Cities

Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Other Conditions in San Francisco